Table 5.

Menopause and diabetes-stratified comparison of Ki67, p4E-BP1 and pAkt between benign/hyperplasia versus atypia/carcinoma

	Benign/hyperplasia	Atypia/carcinoma	P
All cases combined	n=18	n=25
Postmenopausal	n=15	n=17
Ki67	10 (5–20)	50 (40–80)	<0.001
Cytoplasmic pAkt	200 (0–200)	180 (100–190)	0.149
Nuclear pAkt	270 (100–400)	190 (160–200)	0.434
Cytoplasmic p4E-BP1	50 (0–100)	92.5 (30–175)	0.002
Nuclear p4E-BP1	112.5 (5–220)	160 (100–190)	0.004
Premenopausal	n=3	n=8
Ki67	30 (0–70)	70 (40–85)	0.150
Cytoplasmic pAkt	200 (0–200)	110 (0–210)	0.907
Nuclear pAkt	270 (100–400)	180 (120–200)	0.299
Cytoplasmic p4E-BP1	50 (0–100)	100 (0–180)	0.453
Nuclear p4E-BP1	112.5 (5–220)	180 (60–200)	1.000
Diabetic	n=6	n=4
Ki67	15 (5–24)	55 (45–75)	0.010
Cytoplasmic pAkt	135 (10–200)	150 (55–195)	0.823
Nuclear pAkt	150 (100–200)	195 (145–250)	0.662
Cytoplasmic p4E-BP1	5 (0–15)	47.5 (0–147.5)	0.539
Nuclear p4E-BP1	80 (70–100)	145 (75–245)	0.213
Nondiabetic	n=12	n=21
Ki67	10 (4–20)	50 (40–80)	<0.001
Cytoplasmic pAkt	150 (0–185)	175 (100–200)	0.196
Nuclear pAkt	190 (145–260)	150 (150–200)	0.763
Cytoplasmic p4E-BP1	0 (0–40)	100 (30–180)	0.003
Nuclear p4E-BP1	55 (10–125)	170 (95–195)	0.010

Note: The values are expressed as median (interquartile range).

Abbreviations: BMI, body mass index; p4E-BP1, phosphorylated eukaryotic initiation factor 4E binding protein-1; pAkt, phosphorylated Akt.